These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

262 related items for PubMed ID: 22549445

  • 1. Morpholino Oligo Antisense efficiently suppresses BCR/ABL and cell proliferation in CML: specific inhibition of BCR-ABL gene expression by Morpholino Oligo Antisense in BCR-ABL(+) cells.
    Haririan M, Kaviani S, Soleimani M, Ghaemi SR, Delalat B, Atashi A.
    Hematology; 2012 Jan; 17(1):28-34. PubMed ID: 22549445
    [Abstract] [Full Text] [Related]

  • 2. [Overexpression of Shp-2 is associated with the unlimited growth and apoptosis resistance of p210 bcr-abl-mediated chronic myeloid leukemia].
    Zhu XZ, Yu YZ, Fang YM, Liang Y, Lü QH, Xu RZ.
    Zhonghua Yi Xue Za Zhi; 2005 Jul 20; 85(27):1903-6. PubMed ID: 16255985
    [Abstract] [Full Text] [Related]

  • 3. Antisense BCR-ABL oligonucleotides induce apoptosis in the Philadelphia chromosome-positive cell line BV173.
    Smetsers TF, Skorski T, van de Locht LT, Wessels HM, Pennings AH, de Witte T, Calabretta B, Mensink EJ.
    Leukemia; 1994 Jan 20; 8(1):129-40. PubMed ID: 8289478
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of chronic myelogenous leukemia cells harboring a BCR-ABL B3A2 junction by antisense oligonucleotides targeted at the B2A2 junction.
    Mahon FX, Ripoche J, Pigeonnier V, Jazwiec B, Pigneux A, Moreau JF, Reiffers J.
    Exp Hematol; 1995 Dec 20; 23(14):1606-11. PubMed ID: 8542954
    [Abstract] [Full Text] [Related]

  • 5. Restoration of miR-424 suppresses BCR-ABL activity and sensitizes CML cells to imatinib treatment.
    Hershkovitz-Rokah O, Modai S, Pasmanik-Chor M, Toren A, Shomron N, Raanani P, Shpilberg O, Granot G.
    Cancer Lett; 2015 May 01; 360(2):245-56. PubMed ID: 25697481
    [Abstract] [Full Text] [Related]

  • 6. Antisense locked nucleic acids efficiently suppress BCR/ABL and induce cell growth decline and apoptosis in leukemic cells.
    Rapozzi V, Cogoi S, Xodo LE.
    Mol Cancer Ther; 2006 Jul 01; 5(7):1683-92. PubMed ID: 16891454
    [Abstract] [Full Text] [Related]

  • 7. Phosphorothioate BCR-ABL antisense oligonucleotides induce cell death, but fail to reduce cellular bcr-abl protein levels.
    Smetsers TF, van de Locht LT, Pennings AH, Wessels HM, de Witte TM, Mensink EJ.
    Leukemia; 1995 Jan 01; 9(1):118-30. PubMed ID: 7845006
    [Abstract] [Full Text] [Related]

  • 8. Antisense inhibition of P210 bcr-abl in chronic myeloid leukemia.
    Vaerman JL, Lewalle P, Martiat P.
    Stem Cells; 1993 Oct 01; 11 Suppl 3():89-95. PubMed ID: 8298481
    [Abstract] [Full Text] [Related]

  • 9. Disrupting BCR-ABL in combination with secondary leukemia-specific pathways in CML cells leads to enhanced apoptosis and decreased proliferation.
    Woessner DW, Lim CS.
    Mol Pharm; 2013 Jan 07; 10(1):270-7. PubMed ID: 23211037
    [Abstract] [Full Text] [Related]

  • 10. Treatment of Philadelphia leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides.
    Skorski T, Nieborowska-Skorska M, Wlodarski P, Perrotti D, Hoser G, Kawiak J, Majewski M, Christensen L, Iozzo RV, Calabretta B.
    J Natl Cancer Inst; 1997 Jan 15; 89(2):124-33. PubMed ID: 8998181
    [Abstract] [Full Text] [Related]

  • 11. The effect of bcr-abl antisense oligonucleotide on DNA synthesis and apoptosis in K562 chronic myeloid leukemia cells.
    Rowley PT, Keng PC, Kosciolek BA.
    Leuk Res; 1996 Jun 15; 20(6):473-80. PubMed ID: 8709619
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Gene-targeted specific inhibition of chronic myeloid leukemia cell growth by BCR-ABL antisense oligodeoxynucleotides.
    Skórski T, Szczylik C, Malaguarnera L, Calabretta B.
    Folia Histochem Cytobiol; 1991 Jun 15; 29(3):85-9. PubMed ID: 1794439
    [Abstract] [Full Text] [Related]

  • 14. 2',5'-Oligoadenylate-antisense chimeras cause RNase L to selectively degrade bcr/abl mRNA in chronic myelogenous leukemia cells.
    Maran A, Waller CF, Paranjape JM, Li G, Xiao W, Zhang K, Kalaycio ME, Maitra RK, Lichtin AE, Brugger W, Torrence PF, Silverman RH.
    Blood; 1998 Dec 01; 92(11):4336-43. PubMed ID: 9834240
    [Abstract] [Full Text] [Related]

  • 15. [Effect of specific siRNA targeting against bcr-abl chimeric gene on chronic myelogenous leukemia cells].
    Wang S, Chai YB, Liu F, Zhang XY, Jia W, Xie X, Yu WQ, Shang ZC, Jin BQ, Sun BZ.
    Zhonghua Yi Xue Za Zhi; 2005 Jan 19; 85(3):198-202. PubMed ID: 15854468
    [Abstract] [Full Text] [Related]

  • 16. Retrovirally transduced antisense sequences stably suppress P210BCR-ABL expression and inhibit the proliferation of BCR/ABL-containing cell lines.
    Martiat P, Lewalle P, Taj AS, Philippe M, Larondelle Y, Vaerman JL, Wildmann C, Goldman JM, Michaux JL.
    Blood; 1993 Jan 15; 81(2):502-9. PubMed ID: 8422466
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Purging of chronic myelogenous leukemia cells by retrovirally expressed anti-bcr-abl ribozymes with specific cellular compartmentalization.
    Mendoza-Maldonado R, Zentilin L, Fanin R, Giacca M.
    Cancer Gene Ther; 2002 Jan 15; 9(1):71-86. PubMed ID: 11916246
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of P210 expression in chronic myeloid leukaemia: oligonucleotides and/or transduced antisense sequences.
    Lewalle P, Martiat P.
    Leuk Lymphoma; 1993 Jan 15; 11 Suppl 1():139-43. PubMed ID: 8251887
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.